{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:52:58Z","timestamp":1790301178107,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12325-017-0610-z","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T06:07:53Z","timestamp":1507183673000},"page":"2210-2231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development"],"prefix":"10.1007","volume":"34","author":[{"given":"Andrew","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjum","family":"Dadabhoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieternella","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Rummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Badoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"610_CR1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435\u201345.","journal-title":"Blood"},{"issue":"Suppl 3","key":"610_CR2","doi-asserted-by":"publisher","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Ghielmini M, Marcus R, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25(Suppl 3):iii76\u201382.","journal-title":"Ann Oncol."},{"issue":"Suppl 5","key":"610_CR3","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Committee. Ann Oncol. 2015;26(Suppl 5):v116\u201325.","journal-title":"ESMO Guidelines Committee. Ann Oncol"},{"issue":"Suppl 5","key":"610_CR4","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"B Eichhorst","year":"2015","unstructured":"Eichhorst B, Robak T, Montserrat E, ESMO Guidelines Committee., et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78\u201384.","journal-title":"Ann Oncol"},{"key":"610_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Non-Hodgkin lymphoma. 2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf . Accessed 15 June 2017."},{"key":"610_CR6","unstructured":"WHO Model List of Essential Medicines. 19th List (April 2015). http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/ . Accessed 15 June 2017."},{"key":"610_CR7","unstructured":"MabThera EU Summary of Product Characteristics. Roche Registration Limited. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000165\/WC500025821.pdf . Accessed 15 June 2017."},{"key":"610_CR8","unstructured":"Rituxan United States Prescribing Information. 2010. Genentech Inc. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103705s5311lbl.pdf . Accessed 15 June 2017."},{"key":"610_CR9","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","volume":"127","author":"BS Kahl","year":"2016","unstructured":"Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127:2055\u201363.","journal-title":"Blood"},{"key":"610_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22\u201332.","journal-title":"Blood"},{"key":"610_CR11","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood"},{"key":"610_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood-2015-04-585067","volume":"126","author":"N Jain","year":"2015","unstructured":"Jain N, O\u2019Brien S. Initial treatment of CLL: integrating biology and functional status. Blood. 2015;126:463\u201370.","journal-title":"Blood"},{"key":"610_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s002620050016","volume":"48","author":"D Shan","year":"2000","unstructured":"Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673\u201383.","journal-title":"Cancer Immunol Immunother"},{"key":"610_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115\u201323.","journal-title":"Semin Hematol"},{"key":"610_CR15","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","volume":"182","author":"M Leidi","year":"2009","unstructured":"Leidi M, Gotti E, Bologna L, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than M1 cells in vitro. J Immunol. 2009;182:4415\u201322.","journal-title":"J Immunol."},{"key":"610_CR16","first-page":"1183","volume":"2","author":"AR Jazirehi","year":"2003","unstructured":"Jazirehi AR, Gan X-H, De Vos S, et al. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin\u2019s lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2003;2:1183\u201393.","journal-title":"Mol Cancer Ther"},{"key":"610_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-2407-5-103","volume":"5","author":"MR Smith","year":"2005","unstructured":"Smith MR, Joshi I, Jin FF, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin\u2019s lymphoma cell lines in vitro and in scid mice. BMC Cancer. 2005;5:103.","journal-title":"BMC Cancer."},{"key":"610_CR18","first-page":"33","volume":"87","author":"KU Chow","year":"2002","unstructured":"Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87:33\u201343.","journal-title":"Haematologica"},{"key":"610_CR19","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579\u201386.","journal-title":"J Clin Oncol"},{"key":"610_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomized, open-label, phase 3 trial. Lancet. 2010;376:1164\u201374.","journal-title":"Lancet"},{"key":"610_CR21","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","volume":"28","author":"T Robak","year":"2010","unstructured":"Robak T, Dmoszynska A, Solal-C\u00e9ligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756\u201365.","journal-title":"J Clin Oncol"},{"key":"610_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"key":"610_CR23","first-page":"86","volume":"27","author":"M Keating","year":"2000","unstructured":"Keating M, O\u2019Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol. 2000;27:86\u201390.","journal-title":"Semin Oncol"},{"key":"610_CR24","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O\u2019Brien","year":"2001","unstructured":"O\u2019Brien SM, Kantarijan H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165\u201370.","journal-title":"J Clin Oncol"},{"key":"610_CR25","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457\u201366.","journal-title":"Blood"},{"key":"610_CR26","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD-20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927\u201332.","journal-title":"Blood"},{"key":"610_CR27","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.3109\/10428194.2013.877135","volume":"55","author":"S Dakhil","year":"2014","unstructured":"Dakhil S, Hermann R, Schreeder MT, et al. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leuk Lymphoma. 2014;55:2335\u201340.","journal-title":"Leuk Lymphoma"},{"key":"610_CR28","unstructured":"MacGrath I. Cancer in low and middle income countries. In: Carballo, M. Probrook, editors. Health G20: a briefing on health issues for G20 leaders. Sutton, UK, 2010. p. 58\u201368. http:\/\/www.inctr.org\/fileadmin\/user_upload\/inctr-admin\/58-68%20MacGrath_2010%20Final.pdf . Accessed 05 Nov 2016."},{"key":"610_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1196\/annals.1425.011","volume":"1136","author":"DH Peters","year":"2008","unstructured":"Peters DH, Garg A, Bloom G, et al. Poverty and access to health care in developing countries. Ann NY Acad Sci. 2008;1136:161\u201371.","journal-title":"Ann NY Acad Sci."},{"key":"610_CR30","unstructured":"Media release. Roche\u2019s new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma. 2017. http:\/\/www.roche.com\/media\/store\/releases\/med-cor-2014-03-28.htm . Accessed 28 June 2017."},{"key":"610_CR31","unstructured":"Media release: Roche\u2019s subcutaneous formulation of MabThera receives approval in Europe for people with chronic lymphocytic leukaemia. 2017. http:\/\/www.roche.com\/media\/store\/releases\/med-cor-2016-05-31.htm . Accessed 28 June 2017."},{"key":"610_CR32","unstructured":"Media release. FDA Approves Genentech\u2019s RITUXAN HYCELA, a subcutaneous rituximab coformulated with halozyme ENHANZE technology. 2017. http:\/\/www.prnewswire.com\/news-releases\/fda-approves-genentechs-rituxan-hycela-a-subcutaneous-rituximab-coformulated-with-halozyme-enhanze-technology-300478601.html . Accessed 28 June 2017."},{"key":"610_CR33","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/bjc.2013.371","volume":"109","author":"O Shpilberg","year":"2013","unstructured":"Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013;109:1556\u201361.","journal-title":"Br J Cancer"},{"issue":"11","key":"610_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1055\/s-0033-1363993","volume":"64","author":"B Bittner","year":"2014","unstructured":"Bittner B, Richter WF, Hourcade-Potelleret F, et al. Non-clinical pharmacokinetic\/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res (Stuttg). 2014;64(11):569\u201375.","journal-title":"Drug Res (Stuttg)."},{"key":"610_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","volume":"114","author":"LH Bookbinder","year":"2006","unstructured":"Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006;114:230\u201341.","journal-title":"J Control Release"},{"key":"610_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","volume":"36","author":"RL Wasserman","year":"2016","unstructured":"Wasserman RL, Melamed I, Stein MR, et al. Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. J Clin Immunol. 2016;36:571\u201382.","journal-title":"J Clin Immunol"},{"key":"610_CR37","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/01.NAN.0000292572.70387.17","volume":"30","author":"RC Yocum","year":"2007","unstructured":"Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs. 2007;30:293\u20139.","journal-title":"J Infus Nurs."},{"issue":"9","key":"610_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1055\/s-0032-1321831","volume":"62","author":"B Bittner","year":"2012","unstructured":"Bittner B, Richter WF, Hourcade-Potelleret F, et al. Development of a subcutaneous formulation for trastuzumab\u2014nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung. 2012;62(9):401\u20139.","journal-title":"Arzneimittelforschung"},{"key":"610_CR39","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdh176","volume":"15","author":"K Tobinai","year":"2004","unstructured":"Tobinai K, Igarashi T, Itoh K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 2004;15:821\u201330.","journal-title":"Ann Oncol"},{"key":"610_CR40","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","volume":"97","author":"U J\u00e4ger","year":"2012","unstructured":"J\u00e4ger U, Fridrick M, Zeitlinger M, et al. Rituximab serum concentrations during immunochemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97:1431\u20138.","journal-title":"Haematologica"},{"key":"610_CR41","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs. 2013;5:826\u201337.","journal-title":"mAbs"},{"key":"610_CR42","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/0091270009337512","volume":"49","author":"DD Wang","year":"2009","unstructured":"Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49:1012\u201324.","journal-title":"J Clin Pharmacol"},{"key":"610_CR43","doi-asserted-by":"publisher","first-page":"e80533","DOI":"10.1371\/journal.pone.0080533","volume":"8","author":"CP Mao","year":"2013","unstructured":"Mao CP, Brovarney MR, Dabbagh K, et al. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS ONE. 2013;8:e80533.","journal-title":"PLoS ONE"},{"key":"610_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9","author":"A Davies","year":"2017","unstructured":"Davies A, Merli F, Mihaljevi\u0107 B, et al. Efficacy and safety of rituximab subcutaneous versus intravenous in first-line follicular lymphoma: the randomised, open-label, phase III SABRINA study. Lancet Haematol. 2017. doi: 10.1016\/S2352-3026(17)30078-9 (epub ahead of print).","journal-title":"Lancet Haematol."},{"key":"610_CR45","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1200\/JCO.2013.52.2631","volume":"32","author":"A Salar","year":"2014","unstructured":"Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014;32:1782\u201391.","journal-title":"J Clin Oncol"},{"key":"610_CR46","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/bcp.12662","volume":"80","author":"S Assouline","year":"2015","unstructured":"Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2015;80:1001\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"610_CR47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","volume":"15","author":"A Davies","year":"2014","unstructured":"Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15:343\u201352.","journal-title":"Lancet Oncol."},{"key":"610_CR48","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/S2352-3026(16)00004-1","volume":"3","author":"S Assouline","year":"2016","unstructured":"Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016;3:e128\u201338.","journal-title":"Lancet Haematol."},{"key":"610_CR49","doi-asserted-by":"crossref","unstructured":"Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017 (in press).","DOI":"10.3324\/haematol.2017.173583"},{"key":"610_CR50","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456\u201373.","journal-title":"Cancer Treat Rev"},{"key":"610_CR51","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","volume":"28","author":"M Rummel","year":"2017","unstructured":"Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomised, open-label, crossover study (PrefMab). Ann Oncol. 2017;28:836\u201342.","journal-title":"Ann Oncol"},{"key":"610_CR52","doi-asserted-by":"crossref","unstructured":"Rule S, Briones J, Carella AM, et al. Extending subcutaneous rituximab maintenance therapy from 2\u00a0years until progression versus observation in patients with indolent non-Hodgkin\u2019s lymphoma: interim safety data from the MABCUTE study. Blood 2013;122. (ASH annual meeting abstracts, abstract 3052).","DOI":"10.1182\/blood.V122.21.3052.3052"},{"key":"610_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14703","author":"SH Burrows","year":"2017","unstructured":"Burrows SH, Akinbobuyi O, Rule S, Crosbie N. Subcutaneous rituximab can be safely administered without pre-medication. Br J Haematol. 2017. doi: 10.1111\/bjh.14703 (epub ahead of print).","journal-title":"Br J Haematol."},{"issue":"s2","key":"610_CR54","first-page":"1","volume":"102","author":"C Panizo","year":"2017","unstructured":"Panizo C, Bekadja MA, Meddeb B, et al. Safety of subcutaneous administration of rituximab during the first-line treatment of patients with non-Hodgkin lymphoma: the MabRella study. Haematologica. 2017;102(s2):1\u2013882 (P640).","journal-title":"Haematologica."},{"key":"610_CR55","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Gligorov J, M\u00fcller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962\u201370.","journal-title":"Lancet Oncol."},{"issue":"7","key":"610_CR56","doi-asserted-by":"publisher","first-page":"A537","DOI":"10.1016\/j.jval.2014.08.1719","volume":"17","author":"S Rule","year":"2014","unstructured":"Rule S, Briones J, Smith R, et al. Preference for rituximab subcutaneous (SC) and intravenous (IV) among patients with CD20+ non-Hodgkin\u2019s lymphoma (NHL) completing the RASQ measure in randomized phase III studies PREFMAB and MABCUTE. Value Health. 2014;17(7):A537.","journal-title":"Value Health."},{"key":"610_CR57","unstructured":"Lugtenburg P, Rueda A, Avivi I, et al. Patient satisfaction with subcutaneous vs intravenous rituximab combined with CHOP for untreated diffuse large B-cell lymphoma: results from the Phase IIIb MabEase study. Hematol Oncol. 2013;33(Suppl 1). (abstract S383)."},{"key":"610_CR58","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3111\/13696998.2014.914033","volume":"17","author":"S Rule","year":"2014","unstructured":"Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17:459\u201368.","journal-title":"J Med Econ."},{"key":"610_CR59","doi-asserted-by":"publisher","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","volume":"11","author":"E Cock De","year":"2016","unstructured":"De Cock E, Kritikou P, Sandoval M, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11:e0157957. doi: 10.1371\/journal.pone.0157957 (epub ahead of print).","journal-title":"PLoS One"},{"key":"610_CR60","first-page":"227","volume":"8","author":"C Ponzetti","year":"2016","unstructured":"Ponzetti C, Canciani M, Farina M, et al. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin\u2019s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227\u201333.","journal-title":"Clinicoecon Outcomes Res."},{"key":"610_CR61","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1182\/blood-2014-04-563890","volume":"123","author":"BD Cheson","year":"2014","unstructured":"Cheson BD. CLL and NHL: the end of chemotherapy? Blood. 2014;123:3368\u201370.","journal-title":"Blood"},{"key":"610_CR62","unstructured":"Ibrutinib 140\u00a0mg hard capsules. Summary of product characteristics. Janssen-Cilag Limited. Last updated 5 Sept 2016. https:\/\/www.medicines.org.uk\/emc\/medicine\/29383 . Accessed 05 Nov 2016."},{"key":"610_CR63","unstructured":"Idelalisib 100\u00a0mg. Summary of product characteristics. Gilead Sciences Limited. Last updated 27 September 2016. https:\/\/www.medicines.org.uk\/emc\/medicine\/29202 . Accessed 05 Nov 2016."},{"key":"610_CR64","unstructured":"Venetoclax tablets, for oral use. Prescribing information. AbbVie\/Roche Products Limited. Last updated April 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208573s000lbl.pdf . Accessed 05 November 2016."},{"key":"610_CR65","unstructured":"Fludarabine oral 10\u00a0mg tablet. Summary of product characteristics. Sanofi. Last updated 14 October 2015. http:\/\/www.medicines.org.uk\/emc\/medicine\/4240\/ . Accessed 05 Nov 2016."},{"key":"610_CR66","unstructured":"Cyclophosphamide tablets 50\u00a0mg. Baxter Healthcare. Last updated 01 April 2015. https:\/\/www.medicines.org.uk\/emc\/medicine\/30161 . Accessed 05 Nov 2016."},{"key":"610_CR67","doi-asserted-by":"crossref","unstructured":"Davies A, Mihaljevic B, Mercadal S, et al. Longer term efficacy and safety of subcutaneous compared with intravenous rituximab: updated results of the phase 3 SABRINA study. Abstract presented at the American Society of Hematology Annual Meeting 2016, Abstract 1103.","DOI":"10.1182\/blood.V128.22.1103.1103"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0610-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0610-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0610-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T19:20:19Z","timestamp":1603048819000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0610-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0610-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"4 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}